Progyny (NASDAQ:PGNY) Issues Q1 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its first quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.420-0.450 for the period, compared to the consensus estimate of 0.390. The company issued revenue guidance of $319.0 million-$332.0 million, compared to the consensus revenue estimate of $344.9 million. Progyny also updated its FY 2026 guidance to 1.830-1.950 EPS.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on PGNY shares. Barclays initiated coverage on Progyny in a research report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price on the stock. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research report on Monday, December 29th. JPMorgan Chase & Co. set a $35.00 target price on shares of Progyny in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group increased their target price on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus price target of $29.80.

Progyny Stock Up 4.3%

PGNY traded up $0.92 during trading on Thursday, hitting $22.25. 1,852,843 shares of the stock were exchanged, compared to its average volume of 1,438,952. Progyny has a 1-year low of $17.98 and a 1-year high of $28.75. The stock has a fifty day moving average price of $24.16 and a two-hundred day moving average price of $23.14. The firm has a market capitalization of $1.92 billion, a P/E ratio of 35.32, a PEG ratio of 1.31 and a beta of 0.96.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.24). Progyny had a net margin of 4.46% and a return on equity of 10.71%. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts predict that Progyny will post 0.6 EPS for the current year.

Institutional Investors Weigh In On Progyny

A number of institutional investors and hedge funds have recently made changes to their positions in PGNY. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Progyny during the fourth quarter worth about $25,000. Canada Pension Plan Investment Board acquired a new position in Progyny in the 2nd quarter valued at about $77,000. Quarry LP raised its stake in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Progyny by 203.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after acquiring an additional 4,708 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in Progyny during the 4th quarter worth approximately $203,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.